JP2013527758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527758A5 JP2013527758A5 JP2013508401A JP2013508401A JP2013527758A5 JP 2013527758 A5 JP2013527758 A5 JP 2013527758A5 JP 2013508401 A JP2013508401 A JP 2013508401A JP 2013508401 A JP2013508401 A JP 2013508401A JP 2013527758 A5 JP2013527758 A5 JP 2013527758A5
- Authority
- JP
- Japan
- Prior art keywords
- beta
- herpesvirus
- gene product
- gene
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 230000017188 evasion or tolerance of host immune response Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000043129 MHC class I family Human genes 0.000 claims 3
- 108091054437 MHC class I family Proteins 0.000 claims 3
- 230000036755 cellular response Effects 0.000 claims 3
- 230000002950 deficient Effects 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 claims 2
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 claims 2
- 108010038807 Oligopeptides Proteins 0.000 claims 2
- 102000015636 Oligopeptides Human genes 0.000 claims 2
- 101150030723 RIR2 gene Proteins 0.000 claims 2
- 101150037769 TRX2 gene Proteins 0.000 claims 2
- 101150100826 UL40 gene Proteins 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000002845 virion Anatomy 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 101150040913 DUT gene Proteins 0.000 claims 1
- 101150109586 Gk gene Proteins 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 101150041636 NEC1 gene Proteins 0.000 claims 1
- 101150098384 NEC2 gene Proteins 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101150042088 UL16 gene Proteins 0.000 claims 1
- 101150022492 UL83 gene Proteins 0.000 claims 1
- 101150074007 UL99 gene Proteins 0.000 claims 1
- 101150085955 US11 gene Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10004751 | 2010-05-05 | ||
| EP10004751.3 | 2010-05-05 | ||
| EP10005045.9 | 2010-05-12 | ||
| EP10005045 | 2010-05-12 | ||
| PCT/EP2011/002252 WO2011138040A2 (en) | 2010-05-05 | 2011-05-05 | Vaccine against beta-herpesvirus infection and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016019841A Division JP6427514B2 (ja) | 2010-05-05 | 2016-02-04 | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013527758A JP2013527758A (ja) | 2013-07-04 |
| JP2013527758A5 true JP2013527758A5 (enExample) | 2014-06-26 |
Family
ID=44146744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508401A Pending JP2013527758A (ja) | 2010-05-05 | 2011-05-05 | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
| JP2016019841A Active JP6427514B2 (ja) | 2010-05-05 | 2016-02-04 | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016019841A Active JP6427514B2 (ja) | 2010-05-05 | 2016-02-04 | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9078867B2 (enExample) |
| EP (1) | EP2566957B8 (enExample) |
| JP (2) | JP2013527758A (enExample) |
| AU (1) | AU2011250191A1 (enExample) |
| CA (2) | CA2798214C (enExample) |
| ES (1) | ES2679245T3 (enExample) |
| SG (2) | SG185121A1 (enExample) |
| WO (1) | WO2011138040A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2793959C (en) * | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| TR201802741T4 (tr) | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| EP2766385A2 (en) * | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv antigens and uses thereof |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| AU2014225886B2 (en) * | 2013-03-05 | 2020-04-16 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
| US20160243216A1 (en) | 2013-10-29 | 2016-08-25 | The University Of Sydney | Cmv immuno-stimulatory composition |
| CN113528466B (zh) | 2014-07-16 | 2024-12-24 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| SG11201706454VA (en) | 2015-02-10 | 2017-09-28 | Univ Oregon Health & Science | Methods and compositions useful in generating non canonical cd8+ t cell responses |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| BR112019007982A2 (pt) | 2016-10-18 | 2019-07-02 | Univ Oregon Health & Science | vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal |
| WO2020014222A2 (en) * | 2018-07-09 | 2020-01-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Viral promoters and compositions and methods of use thereof |
| US12276665B2 (en) | 2018-07-20 | 2025-04-15 | Aicuris Anti-Infective Cures Ag | Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses |
| WO2022072821A1 (en) * | 2020-10-02 | 2022-04-07 | Colorado State University Research Foundation | Compositions comprising inactivated microbes, and methods for use and production thereof |
| CN116042526B (zh) * | 2022-07-04 | 2023-11-10 | 北京肿瘤医院(北京大学肿瘤医院) | P16基因特异性甲基化的正常人永生化结肠成纤维细胞 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374768B1 (en) | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
| DE19733364A1 (de) * | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| WO2000034497A2 (en) | 1998-12-09 | 2000-06-15 | The General Hospital Corporation | Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors |
| WO2005012545A2 (en) | 2003-07-25 | 2005-02-10 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors |
| EP2497831B1 (en) * | 2004-05-25 | 2014-07-16 | Oregon Health and Science University | TB vaccination using HCMV-based vaccine vectors |
-
2011
- 2011-05-05 SG SG2012080891A patent/SG185121A1/en unknown
- 2011-05-05 ES ES11718950.6T patent/ES2679245T3/es active Active
- 2011-05-05 WO PCT/EP2011/002252 patent/WO2011138040A2/en not_active Ceased
- 2011-05-05 EP EP11718950.6A patent/EP2566957B8/en active Active
- 2011-05-05 CA CA2798214A patent/CA2798214C/en active Active
- 2011-05-05 CA CA3128572A patent/CA3128572C/en active Active
- 2011-05-05 JP JP2013508401A patent/JP2013527758A/ja active Pending
- 2011-05-05 US US13/695,668 patent/US9078867B2/en active Active
- 2011-05-05 SG SG10201503450WA patent/SG10201503450WA/en unknown
- 2011-05-05 AU AU2011250191A patent/AU2011250191A1/en not_active Abandoned
-
2015
- 2015-06-09 US US14/734,415 patent/US20150306210A1/en not_active Abandoned
-
2016
- 2016-02-04 JP JP2016019841A patent/JP6427514B2/ja active Active
-
2018
- 2018-11-19 US US16/194,558 patent/US10842863B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013527758A5 (enExample) | ||
| Li et al. | The future of human DNA vaccines | |
| US10111945B2 (en) | CMV vaccines | |
| US10398769B2 (en) | Influenza nucleic acid molecules and vaccines made therefrom | |
| US20240226291A9 (en) | Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus | |
| JP2014504851A5 (enExample) | ||
| CN110051835A (zh) | 丝状病毒共有抗原、由其制备的核酸构建体和疫苗以及其使用方法 | |
| Yang et al. | Cross-protective efficacy of dendritic cells targeting conserved influenza virus antigen expressed by Lactobacillus plantarum | |
| CN110938604A (zh) | 重组单纯疱疹病毒2(hsv-2)疫苗载体 | |
| JP2016136950A5 (enExample) | ||
| JP2013545448A5 (enExample) | ||
| Bailer et al. | Herpesviral vectors and their application in oncolytic therapy, vaccination, and gene transfer | |
| Tursi et al. | Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity | |
| Jindra et al. | Attenuated recombinant influenza A virus expressing HPV16 E6 and E7 as a novel therapeutic vaccine approach | |
| Di et al. | The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice | |
| US11976305B2 (en) | Lassa vaccine | |
| Hyoung et al. | A consensus-hemagglutinin-based vaccine delivered by an attenuated Salmonella mutant protects chickens against heterologous H7N1 influenza virus | |
| AU2019262056B2 (en) | HSV-2-delta-gD vaccines and methods for their production and use | |
| CN110234358A (zh) | 多病毒特异性的t细胞免疫疗法 | |
| He et al. | Antigen epitope-expressing cytokines for DNA immunization | |
| EP3562504B1 (en) | Dna vaccine comprising a polynucleotide sequence encoding a fusion protein encompassing a plant protein signal sequence | |
| JP2023011701A (ja) | Ｃｄ４０およびｓｔｉｎｇ経路を活性化する遺伝子アジュバントの発現のためのウイルスベクター構築物 | |
| US20220265816A1 (en) | Use of the agent for induction of specific immunity against severe acute respiratory syndrome virus sars-cov-2 for revaccination of population (variants) | |
| WO2022177466A1 (en) | The use of the agent for inducing immunity to sars-cov-2 | |
| Chapon | Optimizing innate immune signals to enhance antigen-specific adaptive responses |